Conference Day Two
8:25 am Chair’s Opening Remarks
Addressing Clinical Challenges to Accelerate the Route to Commercialization
8:30 am Securing Scalable Manufacturing for TCR Therapies to Guarantee Potency In Vivo
Synopsis
- Translating scalable expansion protocol from research to clinical scale
- Incorporating successful engineering into manufacturing protocol to produce genetically stable products
- Guaranteeing reproducibility of TCR products to optimize TCR manufacturing
9:00 am Leveraging Biomarkers for Patient Stratification in Clinical Trials & Beyond
Synopsis
- Defining an RNA threshold guided by in-house mass spectrometry data to distinguish target-positive patients for Immatics TCR-based therapeutic drug candidates
- Development of an RT-qPCR-based biomarker assay (IMADetect®) for patient eligibility testing in clinical trials
- Clinical experience with IMADetect® and further development
9:30 am VIRTUAL TALK Case Study Spotlight: Sharing Experiences from Commercializing the First TCR Therapy
Synopsis
Hear first-hand experiences and gain insights into the commercialization of the first TCR-based therapy: KIMMTRAK®, a TCR bispecific approved in the US and Europe
10:00 am Morning Refreshment Break & Networking
Expanding Techniques to Drive Durability in the Solid Tumor Microenvironment
11:00 am Evaluating & Utilizing Combinations or Co-Stimulatory Molecules to Boost Therapy Durability
Synopsis
- Exploring the range of possible combination therapies
- Administering immune checkpoint inhibitors to accelerate tumor killing
- Proving chosen combinations are safe to administer to patients
11:30 am Engineering Cells to Armor Against the Hostile Tumor Microenvironment
Synopsis
- Utilizing good quality cells to increase T-cell fitness in vivo
- Understanding why durability is limited to recognize engineering potential
- Equipping T-cells with the ability to persist in the microenvironment
12:00 pm Lunch Break & Networking
1:00 pm Natural Activation of T-Cells Through the TAC Receptor Provides Ideal Characteristics for Adoptive Cell Therapy
Synopsis
- Unique structure and biology of TAC T-cells
- Deep penetration and activation of TAC T-cells into solid tumors
- Update on TAC01-HER2 Phase I/II clinical trial in patients with HER2-overexpressing solid tumors
1:30 pm Flipping the Script on the Tumor Microenvironment: Supercharging MAGEA4-Targeting T-Cells to Resist Tumor Immunosuppression
Synopsis
- We have identified a highly selective and active MAGEA4-directed, HLA-A02-restricted TCR
- To combat the effects of TGFβ, a potent immunosuppressive factor often coexpressed in MAGEA4+ solid tumors, we have developed CTBR12, a flip receptor that converts TGFβ activity into a proliferative T-cell activation signal
- Preclinical in vitro and in vivo models demonstrate potent tumor control of our MAGEA4 TCR + CTBR12 development candidate superior to the TCR alone – supporting the clinical development of this novel construct
Boosting TCR Discovery to Maximize Targeting Potential & Power
2:00 pm Systematic Isolation & Characterization of Clinical TCR Candidates
Synopsis
- Native and optimized TCR frameworks
- TCR cross-reactivity – insights and practical benchmarks
- Preventing TCR allo-reactivity
2:30 pm Afternoon Break & Refreshments
3:00 pm Mediating Successful Discovery of ‘Good’ TCRs that will Successfully Translate into the Clinic
Synopsis
- Classifying what a ‘good’ TCR looks like in terms of affinity, cross-reactivity and safety
- Screening and removing non-specific TCRs to guarantee tumor specificity
- Advancing technology to increase efficiency of discovery
3:30 pm Combining Best-in-Class TCRs, Next Generation Technologies & Optimal Manufacturing to Mediate Optimal Anti-Tumor Response
Synopsis
- MyT platformTM, a unique T-cell receptor and unbiased epitope discovery engine
- Next-generation approaches to engage the broader immune system and promote resistance to the tumor microenvironment
- Process development that selects for memory phenotype
4:00 pm All-Natural & High-Affinity TCR Enable CD8-Independent Func
Synopsis
- Discovery and validation of 806TCR using proprietary iSORT platform
- Empower CD4 T helper cells by transducing 806TCR
- CD8-independence makes 806TCR an excellent candidate for allogeneic and “off the shelf” modalities
4:30 pm Close of Conference Day Two
